The FDA-approved therapies for FD in the US include: (1) enzyme replacement therapies (agalsidase-beta [approved in 2003] and pegunigalsidase-alpha [approved in 2023]) and (2) chaperone therapy, migalastat (approved in 2018), indicated only for patients with specific variants of the GLA gene [13–15]. The gene discussed is GLA; the disease is Fabry disease.